#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


Text=Alcohol Affects Brain Functional Connectivity and its Coupling with Behavior: Greater Effects in Male Heavy Drinkers Acute and chronic alcohol exposure significantly affect behavior but the underlying neurobiological mechanisms are still poorly understood.
1-1	0-7	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
1-2	8-15	Affects	_
1-3	16-21	Brain	_
1-4	22-32	Functional	_
1-5	33-45	Connectivity	_
1-6	46-49	and	_
1-7	50-53	its	_
1-8	54-62	Coupling	_
1-9	63-67	with	_
1-10	68-76	Behavior	_
1-11	77-78	:	_
1-12	79-86	Greater	_
1-13	87-94	Effects	_
1-14	95-97	in	_
1-15	98-102	Male	http://maven.renci.org/NeuroBridge/neurobridge#ReproductiveDisease
1-16	103-108	Heavy	http://maven.renci.org/NeuroBridge/neurobridge#ReproductiveDisease
1-17	109-117	Drinkers	http://maven.renci.org/NeuroBridge/neurobridge#ReproductiveDisease
1-18	118-123	Acute	_
1-19	124-127	and	_
1-20	128-135	chronic	_
1-21	136-143	alcohol	_
1-22	144-152	exposure	_
1-23	153-166	significantly	_
1-24	167-173	affect	_
1-25	174-182	behavior	_
1-26	183-186	but	_
1-27	187-190	the	_
1-28	191-201	underlying	_
1-29	202-217	neurobiological	_
1-30	218-228	mechanisms	_
1-31	229-232	are	_
1-32	233-238	still	_
1-33	239-245	poorly	_
1-34	246-256	understood	_
1-35	257-258	.	_

Text=Here we used functional connectivity density (FCD) mapping to study alcohol-related changes in resting brain activity and their association with behavior.
2-1	259-263	Here	_
2-2	264-266	we	_
2-3	267-271	used	_
2-4	272-282	functional	_
2-5	283-295	connectivity	_
2-6	296-303	density	_
2-7	304-305	(	_
2-8	306-309	FCD	_
2-9	310-311	)	_
2-10	312-319	mapping	_
2-11	320-322	to	_
2-12	323-328	study	_
2-13	329-344	alcohol-related	_
2-14	345-352	changes	_
2-15	353-355	in	_
2-16	356-363	resting	_
2-17	364-369	brain	_
2-18	370-378	activity	_
2-19	379-382	and	_
2-20	383-388	their	_
2-21	389-400	association	_
2-22	401-405	with	_
2-23	406-414	behavior	_
2-24	415-416	.	_

Text=Heavy drinkers (HD; N=16; 16 males) and normal controls (NM; N=24; 14 males) were tested after placebo and after acute alcohol administration.
3-1	417-422	Heavy	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
3-2	423-431	drinkers	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
3-3	432-433	(	_
3-4	434-436	HD	_
3-5	437-438	;	_
3-6	439-443	N=16	_
3-7	444-445	;	_
3-8	446-448	16	_
3-9	449-454	males	_
3-10	455-456	)	_
3-11	457-460	and	_
3-12	461-467	normal	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
3-13	468-476	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
3-14	477-478	(	_
3-15	479-481	NM	_
3-16	482-483	;	_
3-17	484-488	N=24	_
3-18	489-490	;	_
3-19	491-493	14	_
3-20	494-499	males	_
3-21	500-501	)	_
3-22	502-506	were	_
3-23	507-513	tested	_
3-24	514-519	after	_
3-25	520-527	placebo	_
3-26	528-531	and	_
3-27	532-537	after	_
3-28	538-543	acute	_
3-29	544-551	alcohol	_
3-30	552-566	administration	_
3-31	567-568	.	_

Text=Group comparisons showed that NM had higher FCD in visual and prefrontal cortices, default-mode network regions, and thalamus, while HD had higher FCD in cerebellum.
4-1	569-574	Group	_
4-2	575-586	comparisons	_
4-3	587-593	showed	_
4-4	594-598	that	_
4-5	599-601	NM	_
4-6	602-605	had	_
4-7	606-612	higher	_
4-8	613-616	FCD	_
4-9	617-619	in	_
4-10	620-626	visual	_
4-11	627-630	and	_
4-12	631-641	prefrontal	_
4-13	642-650	cortices	_
4-14	651-652	,	_
4-15	653-665	default-mode	_
4-16	666-673	network	_
4-17	674-681	regions	_
4-18	682-683	,	_
4-19	684-687	and	_
4-20	688-696	thalamus	_
4-21	697-698	,	_
4-22	699-704	while	_
4-23	705-707	HD	_
4-24	708-711	had	_
4-25	712-718	higher	_
4-26	719-722	FCD	_
4-27	723-725	in	_
4-28	726-736	cerebellum	_
4-29	737-738	.	_

Text=Acute alcohol significantly increased FCD within the thalamus, impaired cognitive and motor functions, and affected self-reports of mood/drug effects in both groups.
5-1	739-744	Acute	_
5-2	745-752	alcohol	_
5-3	753-766	significantly	_
5-4	767-776	increased	_
5-5	777-780	FCD	_
5-6	781-787	within	_
5-7	788-791	the	_
5-8	792-800	thalamus	_
5-9	801-802	,	_
5-10	803-811	impaired	_
5-11	812-821	cognitive	_
5-12	822-825	and	_
5-13	826-831	motor	_
5-14	832-841	functions	_
5-15	842-843	,	_
5-16	844-847	and	_
5-17	848-856	affected	_
5-18	857-869	self-reports	_
5-19	870-872	of	_
5-20	873-882	mood/drug	_
5-21	883-890	effects	_
5-22	891-893	in	_
5-23	894-898	both	_
5-24	899-905	groups	_
5-25	906-907	.	_

Text=Partial least squares regression showed alcohol-induced changes in mood/drug effects were associated with changes in thalamic FCD in both groups.
6-1	908-915	Partial	_
6-2	916-921	least	_
6-3	922-929	squares	_
6-4	930-940	regression	_
6-5	941-947	showed	_
6-6	948-963	alcohol-induced	_
6-7	964-971	changes	_
6-8	972-974	in	_
6-9	975-984	mood/drug	_
6-10	985-992	effects	_
6-11	993-997	were	_
6-12	998-1008	associated	_
6-13	1009-1013	with	_
6-14	1014-1021	changes	_
6-15	1022-1024	in	_
6-16	1025-1033	thalamic	_
6-17	1034-1037	FCD	_
6-18	1038-1040	in	_
6-19	1041-1045	both	_
6-20	1046-1052	groups	_
6-21	1053-1054	.	_

Text=Disruptions in motor function were associated with increases in cerebellar FCD in NM and thalamus FCD in HD.
7-1	1055-1066	Disruptions	_
7-2	1067-1069	in	_
7-3	1070-1075	motor	_
7-4	1076-1084	function	_
7-5	1085-1089	were	_
7-6	1090-1100	associated	_
7-7	1101-1105	with	_
7-8	1106-1115	increases	_
7-9	1116-1118	in	_
7-10	1119-1129	cerebellar	_
7-11	1130-1133	FCD	_
7-12	1134-1136	in	_
7-13	1137-1139	NM	_
7-14	1140-1143	and	_
7-15	1144-1152	thalamus	_
7-16	1153-1156	FCD	_
7-17	1157-1159	in	_
7-18	1160-1162	HD	_
7-19	1163-1164	.	_

Text=Alcohol-induced declines in cognitive performance were associated with connectivity increases in visual cortex and thalamus in NM, but in HD, increases in precuneus FCD were associated with improved cognitive performance.
8-1	1165-1180	Alcohol-induced	_
8-2	1181-1189	declines	_
8-3	1190-1192	in	_
8-4	1193-1202	cognitive	_
8-5	1203-1214	performance	_
8-6	1215-1219	were	_
8-7	1220-1230	associated	_
8-8	1231-1235	with	_
8-9	1236-1248	connectivity	_
8-10	1249-1258	increases	_
8-11	1259-1261	in	_
8-12	1262-1268	visual	_
8-13	1269-1275	cortex	_
8-14	1276-1279	and	_
8-15	1280-1288	thalamus	_
8-16	1289-1291	in	_
8-17	1292-1294	NM	_
8-18	1295-1296	,	_
8-19	1297-1300	but	_
8-20	1301-1303	in	_
8-21	1304-1306	HD	_
8-22	1307-1308	,	_
8-23	1309-1318	increases	_
8-24	1319-1321	in	_
8-25	1322-1331	precuneus	_
8-26	1332-1335	FCD	_
8-27	1336-1340	were	_
8-28	1341-1351	associated	_
8-29	1352-1356	with	_
8-30	1357-1365	improved	_
8-31	1366-1375	cognitive	_
8-32	1376-1387	performance	_
8-33	1388-1389	.	_

Text=Acute alcohol reduced “ neurocognitive coupling ”, the association between behavioral performance and FCD (indexing brain activity), an effect that was accentuated in HD compared to NM.
9-1	1390-1395	Acute	_
9-2	1396-1403	alcohol	_
9-3	1404-1411	reduced	_
9-4	1412-1413	“	_
9-5	1414-1428	neurocognitive	_
9-6	1429-1437	coupling	_
9-7	1438-1439	”	_
9-8	1440-1441	,	_
9-9	1442-1445	the	_
9-10	1446-1457	association	_
9-11	1458-1465	between	_
9-12	1466-1476	behavioral	_
9-13	1477-1488	performance	_
9-14	1489-1492	and	_
9-15	1493-1496	FCD	_
9-16	1497-1498	(	_
9-17	1499-1507	indexing	_
9-18	1508-1513	brain	_
9-19	1514-1522	activity	_
9-20	1523-1524	)	_
9-21	1525-1526	,	_
9-22	1527-1529	an	_
9-23	1530-1536	effect	_
9-24	1537-1541	that	_
9-25	1542-1545	was	_
9-26	1546-1557	accentuated	_
9-27	1558-1560	in	_
9-28	1561-1563	HD	_
9-29	1564-1572	compared	_
9-30	1573-1575	to	_
9-31	1576-1578	NM	_
9-32	1579-1580	.	_

Text=Findings suggest that reduced cortical connectivity in HD contribute to decline in cognitive abilities associated with heavy alcohol consumption, whereas increased cerebellar connectivity in HD may have compensatory effects on behavioral performance.
10-1	1581-1589	Findings	_
10-2	1590-1597	suggest	_
10-3	1598-1602	that	_
10-4	1603-1610	reduced	_
10-5	1611-1619	cortical	_
10-6	1620-1632	connectivity	_
10-7	1633-1635	in	_
10-8	1636-1638	HD	http://maven.renci.org/NeuroBridge/neurobridge#Thing
10-9	1639-1649	contribute	_
10-10	1650-1652	to	_
10-11	1653-1660	decline	_
10-12	1661-1663	in	_
10-13	1664-1673	cognitive	_
10-14	1674-1683	abilities	_
10-15	1684-1694	associated	_
10-16	1695-1699	with	_
10-17	1700-1705	heavy	_
10-18	1706-1713	alcohol	_
10-19	1714-1725	consumption	_
10-20	1726-1727	,	_
10-21	1728-1735	whereas	_
10-22	1736-1745	increased	_
10-23	1746-1756	cerebellar	_
10-24	1757-1769	connectivity	_
10-25	1770-1772	in	_
10-26	1773-1775	HD	http://maven.renci.org/NeuroBridge/neurobridge#Thing
10-27	1776-1779	may	_
10-28	1780-1784	have	_
10-29	1785-1797	compensatory	_
10-30	1798-1805	effects	_
10-31	1806-1808	on	_
10-32	1809-1819	behavioral	_
10-33	1820-1831	performance	_
10-34	1832-1833	.	_

Text=The results reveal how drinking history alters the association between brain functional connectivity density and individual differences in behavioral performance.
11-1	1834-1837	The	_
11-2	1838-1845	results	_
11-3	1846-1852	reveal	_
11-4	1853-1856	how	_
11-5	1857-1865	drinking	_
11-6	1866-1873	history	_
11-7	1874-1880	alters	_
11-8	1881-1884	the	_
11-9	1885-1896	association	_
11-10	1897-1904	between	_
11-11	1905-1910	brain	_
11-12	1911-1921	functional	_
11-13	1922-1934	connectivity	_
11-14	1935-1942	density	_
11-15	1943-1946	and	_
11-16	1947-1957	individual	_
11-17	1958-1969	differences	_
11-18	1970-1972	in	_
11-19	1973-1983	behavioral	_
11-20	1984-1995	performance	_
11-21	1996-1997	.	_

Text=Methods Participants We studied two groups of participants: 16 heavy drinkers (HD; age: M = 34.6 years; SD = 9.70 years; 16 males) and 24 normal controls (NM; age: M = 32.5 years; SD = 6.39 years; 14 males).
12-1	1998-2005	Methods	http://maven.renci.org/NeuroBridge/neurobridge#DataCollectionMethod
12-2	2006-2018	Participants	_
12-3	2019-2021	We	_
12-4	2022-2029	studied	_
12-5	2030-2033	two	_
12-6	2034-2040	groups	_
12-7	2041-2043	of	_
12-8	2044-2056	participants	_
12-9	2057-2058	:	_
12-10	2059-2061	16	_
12-11	2062-2067	heavy	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
12-12	2068-2076	drinkers	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
12-13	2077-2078	(	_
12-14	2079-2081	HD	_
12-15	2082-2083	;	_
12-16	2084-2087	age	_
12-17	2088-2089	:	_
12-18	2090-2091	M	_
12-19	2092-2093	=	_
12-20	2094-2098	34.6	_
12-21	2099-2104	years	_
12-22	2105-2106	;	_
12-23	2107-2109	SD	_
12-24	2110-2111	=	_
12-25	2112-2116	9.70	_
12-26	2117-2122	years	_
12-27	2123-2124	;	_
12-28	2125-2127	16	_
12-29	2128-2133	males	_
12-30	2134-2135	)	_
12-31	2136-2139	and	_
12-32	2140-2142	24	_
12-33	2143-2149	normal	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
12-34	2150-2158	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
12-35	2159-2160	(	_
12-36	2161-2163	NM	_
12-37	2164-2165	;	_
12-38	2166-2169	age	_
12-39	2170-2171	:	_
12-40	2172-2173	M	_
12-41	2174-2175	=	_
12-42	2176-2180	32.5	_
12-43	2181-2186	years	_
12-44	2187-2188	;	_
12-45	2189-2191	SD	_
12-46	2192-2193	=	_
12-47	2194-2198	6.39	_
12-48	2199-2204	years	_
12-49	2205-2206	;	_
12-50	2207-2209	14	_
12-51	2210-2215	males	_
12-52	2216-2217	)	_
12-53	2218-2219	.	_

Text=Out of 48 planned participants for both groups, these subjects completed required MRI sessions.
13-1	2220-2223	Out	_
13-2	2224-2226	of	_
13-3	2227-2229	48	_
13-4	2230-2237	planned	_
13-5	2238-2250	participants	_
13-6	2251-2254	for	_
13-7	2255-2259	both	_
13-8	2260-2266	groups	_
13-9	2267-2268	,	_
13-10	2269-2274	these	_
13-11	2275-2283	subjects	_
13-12	2284-2293	completed	_
13-13	2294-2302	required	_
13-14	2303-2306	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
13-15	2307-2315	sessions	_
13-16	2316-2317	.	_

Text=We predicted at α = 0.05 and 80% power, this sample size would allow to detect large group and condition effects on FCD (Cohen ’ s d = 0.9; r = 0.5).
14-1	2318-2320	We	_
14-2	2321-2330	predicted	_
14-3	2331-2333	at	_
14-4	2334-2335	α	_
14-5	2336-2337	=	_
14-6	2338-2342	0.05	_
14-7	2343-2346	and	_
14-8	2347-2349	80	_
14-9	2350-2351	%	_
14-10	2352-2357	power	_
14-11	2358-2359	,	_
14-12	2360-2364	this	_
14-13	2365-2371	sample	_
14-14	2372-2376	size	_
14-15	2377-2382	would	_
14-16	2383-2388	allow	_
14-17	2389-2391	to	_
14-18	2392-2398	detect	_
14-19	2399-2404	large	_
14-20	2405-2410	group	_
14-21	2411-2414	and	_
14-22	2415-2424	condition	_
14-23	2425-2432	effects	_
14-24	2433-2435	on	_
14-25	2436-2439	FCD	_
14-26	2440-2441	(	_
14-27	2442-2447	Cohen	_
14-28	2448-2449	’	_
14-29	2450-2451	s	_
14-30	2452-2453	d	_
14-31	2454-2455	=	_
14-32	2456-2459	0.9	_
14-33	2460-2461	;	_
14-34	2462-2463	r	_
14-35	2464-2465	=	_
14-36	2466-2469	0.5	_
14-37	2470-2471	)	_
14-38	2472-2473	.	_

Text=The inclusion criterion for HD was 5 or more drinks a day on 3 or more occasions per week.
15-1	2474-2477	The	_
15-2	2478-2487	inclusion	_
15-3	2488-2497	criterion	_
15-4	2498-2501	for	_
15-5	2502-2504	HD	_
15-6	2505-2508	was	_
15-7	2509-2510	5	_
15-8	2511-2513	or	_
15-9	2514-2518	more	_
15-10	2519-2525	drinks	_
15-11	2526-2527	a	_
15-12	2528-2531	day	_
15-13	2532-2534	on	_
15-14	2535-2536	3	_
15-15	2537-2539	or	_
15-16	2540-2544	more	_
15-17	2545-2554	occasions	_
15-18	2555-2558	per	_
15-19	2559-2563	week	_
15-20	2564-2565	.	_

Text=The HD reported their last use of alcohol within 3 days of the MRI scans.
16-1	2566-2569	The	_
16-2	2570-2572	HD	_
16-3	2573-2581	reported	_
16-4	2582-2587	their	_
16-5	2588-2592	last	_
16-6	2593-2596	use	_
16-7	2597-2599	of	_
16-8	2600-2607	alcohol	_
16-9	2608-2614	within	_
16-10	2615-2616	3	_
16-11	2617-2621	days	_
16-12	2622-2624	of	_
16-13	2625-2628	the	_
16-14	2629-2632	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
16-15	2633-2638	scans	_
16-16	2639-2640	.	_

Text=In order to maximize group differences, for NM group we included participants with light drinking history of no more than one drink a day.
17-1	2641-2643	In	_
17-2	2644-2649	order	_
17-3	2650-2652	to	_
17-4	2653-2661	maximize	_
17-5	2662-2667	group	_
17-6	2668-2679	differences	_
17-7	2680-2681	,	_
17-8	2682-2685	for	_
17-9	2686-2688	NM	_
17-10	2689-2694	group	_
17-11	2695-2697	we	_
17-12	2698-2706	included	_
17-13	2707-2719	participants	_
17-14	2720-2724	with	_
17-15	2725-2730	light	_
17-16	2731-2739	drinking	_
17-17	2740-2747	history	_
17-18	2748-2750	of	_
17-19	2751-2753	no	_
17-20	2754-2758	more	_
17-21	2759-2763	than	_
17-22	2764-2767	one	_
17-23	2768-2773	drink	_
17-24	2774-2775	a	_
17-25	2776-2779	day	_
17-26	2780-2781	.	_

Text=Because we did not want to give alcohol for the first time to an individual without any alcohol experience, NM also had to have prior experience with alcohol.
18-1	2782-2789	Because	_
18-2	2790-2792	we	_
18-3	2793-2796	did	_
18-4	2797-2800	not	_
18-5	2801-2805	want	_
18-6	2806-2808	to	_
18-7	2809-2813	give	_
18-8	2814-2821	alcohol	_
18-9	2822-2825	for	_
18-10	2826-2829	the	_
18-11	2830-2835	first	_
18-12	2836-2840	time	_
18-13	2841-2843	to	_
18-14	2844-2846	an	_
18-15	2847-2857	individual	_
18-16	2858-2865	without	_
18-17	2866-2869	any	_
18-18	2870-2877	alcohol	_
18-19	2878-2888	experience	_
18-20	2889-2890	,	_
18-21	2891-2893	NM	_
18-22	2894-2898	also	_
18-23	2899-2902	had	_
18-24	2903-2905	to	_
18-25	2906-2910	have	_
18-26	2911-2916	prior	_
18-27	2917-2927	experience	_
18-28	2928-2932	with	_
18-29	2933-2940	alcohol	_
18-30	2941-2942	.	_

Text=Exclusion criteria were: 1) urine positive for psychotropic drugs; 2) present or past history of dependence on alcohol or other drugs of abuse (except nicotine and allowed diagnosis of alcohol abuse though not dependence for HD); 3) present or past history of neurological or psychiatric disorder; 4) use of psychoactive medications in the past month (i.e., opiate analgesics, stimulants, sedatives); 5) use of prescription (non-psychiatric) medication (s), i.e., antihistamines; 6) medical conditions that may alter cerebral function; 7) cardiovascular and metabolic diseases and 8) history of head trauma with loss of consciousness of more than 30 min.
19-1	2943-2952	Exclusion	_
19-2	2953-2961	criteria	_
19-3	2962-2966	were	_
19-4	2967-2968	:	_
19-5	2969-2970	1	_
19-6	2971-2972	)	_
19-7	2973-2978	urine	_
19-8	2979-2987	positive	_
19-9	2988-2991	for	_
19-10	2992-3004	psychotropic	_
19-11	3005-3010	drugs	_
19-12	3011-3012	;	_
19-13	3013-3014	2	_
19-14	3015-3016	)	_
19-15	3017-3024	present	_
19-16	3025-3027	or	_
19-17	3028-3032	past	_
19-18	3033-3040	history	_
19-19	3041-3043	of	_
19-20	3044-3054	dependence	_
19-21	3055-3057	on	_
19-22	3058-3065	alcohol	_
19-23	3066-3068	or	_
19-24	3069-3074	other	_
19-25	3075-3080	drugs	_
19-26	3081-3083	of	_
19-27	3084-3089	abuse	_
19-28	3090-3091	(	_
19-29	3092-3098	except	_
19-30	3099-3107	nicotine	_
19-31	3108-3111	and	_
19-32	3112-3119	allowed	_
19-33	3120-3129	diagnosis	_
19-34	3130-3132	of	_
19-35	3133-3140	alcohol	_
19-36	3141-3146	abuse	_
19-37	3147-3153	though	_
19-38	3154-3157	not	_
19-39	3158-3168	dependence	_
19-40	3169-3172	for	_
19-41	3173-3175	HD	_
19-42	3176-3177	)	_
19-43	3178-3179	;	_
19-44	3180-3181	3	_
19-45	3182-3183	)	_
19-46	3184-3191	present	_
19-47	3192-3194	or	_
19-48	3195-3199	past	_
19-49	3200-3207	history	_
19-50	3208-3210	of	_
19-51	3211-3223	neurological	_
19-52	3224-3226	or	_
19-53	3227-3238	psychiatric	_
19-54	3239-3247	disorder	_
19-55	3248-3249	;	_
19-56	3250-3251	4	_
19-57	3252-3253	)	_
19-58	3254-3257	use	_
19-59	3258-3260	of	_
19-60	3261-3273	psychoactive	_
19-61	3274-3285	medications	_
19-62	3286-3288	in	_
19-63	3289-3292	the	_
19-64	3293-3297	past	_
19-65	3298-3303	month	_
19-66	3304-3305	(	_
19-67	3306-3310	i.e.	_
19-68	3311-3312	,	_
19-69	3313-3319	opiate	_
19-70	3320-3330	analgesics	_
19-71	3331-3332	,	_
19-72	3333-3343	stimulants	_
19-73	3344-3345	,	_
19-74	3346-3355	sedatives	_
19-75	3356-3357	)	_
19-76	3358-3359	;	_
19-77	3360-3361	5	_
19-78	3362-3363	)	_
19-79	3364-3367	use	_
19-80	3368-3370	of	_
19-81	3371-3383	prescription	_
19-82	3384-3385	(	_
19-83	3386-3401	non-psychiatric	_
19-84	3402-3403	)	_
19-85	3404-3414	medication	_
19-86	3415-3416	(	_
19-87	3417-3418	s	_
19-88	3419-3420	)	_
19-89	3421-3422	,	_
19-90	3423-3427	i.e.	_
19-91	3428-3429	,	_
19-92	3430-3444	antihistamines	_
19-93	3445-3446	;	_
19-94	3447-3448	6	_
19-95	3449-3450	)	_
19-96	3451-3458	medical	_
19-97	3459-3469	conditions	_
19-98	3470-3474	that	_
19-99	3475-3478	may	_
19-100	3479-3484	alter	_
19-101	3485-3493	cerebral	_
19-102	3494-3502	function	_
19-103	3503-3504	;	_
19-104	3505-3506	7	_
19-105	3507-3508	)	_
19-106	3509-3523	cardiovascular	_
19-107	3524-3527	and	_
19-108	3528-3537	metabolic	_
19-109	3538-3546	diseases	_
19-110	3547-3550	and	_
19-111	3551-3552	8	_
19-112	3553-3554	)	_
19-113	3555-3562	history	_
19-114	3563-3565	of	_
19-115	3566-3570	head	_
19-116	3571-3577	trauma	_
19-117	3578-3582	with	_
19-118	3583-3587	loss	_
19-119	3588-3590	of	_
19-120	3591-3604	consciousness	_
19-121	3605-3607	of	_
19-122	3608-3612	more	_
19-123	3613-3617	than	_
19-124	3618-3620	30	_
19-125	3621-3624	min	_
19-126	3625-3626	.	_

Text=Signed informed consents were obtained from the subjects prior to participation, approved by the Committee on Research in Human Subjects at Stony Brook University (IRBNet ID: 137462, CORIHS ID: 20090792).
20-1	3627-3633	Signed	_
20-2	3634-3642	informed	_
20-3	3643-3651	consents	_
20-4	3652-3656	were	_
20-5	3657-3665	obtained	_
20-6	3666-3670	from	_
20-7	3671-3674	the	_
20-8	3675-3683	subjects	_
20-9	3684-3689	prior	_
20-10	3690-3692	to	_
20-11	3693-3706	participation	_
20-12	3707-3708	,	_
20-13	3709-3717	approved	_
20-14	3718-3720	by	_
20-15	3721-3724	the	_
20-16	3725-3734	Committee	_
20-17	3735-3737	on	_
20-18	3738-3746	Research	_
20-19	3747-3749	in	_
20-20	3750-3755	Human	_
20-21	3756-3764	Subjects	_
20-22	3765-3767	at	_
20-23	3768-3773	Stony	_
20-24	3774-3779	Brook	_
20-25	3780-3790	University	_
20-26	3791-3792	(	_
20-27	3793-3799	IRBNet	_
20-28	3800-3802	ID	_
20-29	3803-3804	:	_
20-30	3805-3811	137462	_
20-31	3812-3813	,	_
20-32	3814-3820	CORIHS	_
20-33	3821-3823	ID	_
20-34	3824-3825	:	_
20-35	3826-3834	20090792	_
20-36	3835-3836	)	_
20-37	3837-3838	.	_

Text=Alcohol and placebo administration Each participant was tested on separate days (maximum 3 days apart) to assess the effects of alcohol (ALC) and placebo (PLC).
21-1	3839-3846	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
21-2	3847-3850	and	_
21-3	3851-3858	placebo	_
21-4	3859-3873	administration	_
21-5	3874-3878	Each	_
21-6	3879-3890	participant	_
21-7	3891-3894	was	_
21-8	3895-3901	tested	_
21-9	3902-3904	on	_
21-10	3905-3913	separate	_
21-11	3914-3918	days	_
21-12	3919-3920	(	_
21-13	3921-3928	maximum	_
21-14	3929-3930	3	_
21-15	3931-3935	days	_
21-16	3936-3941	apart	_
21-17	3942-3943	)	_
21-18	3944-3946	to	_
21-19	3947-3953	assess	_
21-20	3954-3957	the	_
21-21	3958-3965	effects	_
21-22	3966-3968	of	_
21-23	3969-3976	alcohol	_
21-24	3977-3978	(	_
21-25	3979-3982	ALC	_
21-26	3983-3984	)	_
21-27	3985-3988	and	_
21-28	3989-3996	placebo	_
21-29	3997-3998	(	_
21-30	3999-4002	PLC	_
21-31	4003-4004	)	_
21-32	4005-4006	.	_

Text=The order of ALC and PLC conditions was randomly assigned across subjects (single blinded).
22-1	4007-4010	The	_
22-2	4011-4016	order	_
22-3	4017-4019	of	_
22-4	4020-4023	ALC	_
22-5	4024-4027	and	_
22-6	4028-4031	PLC	_
22-7	4032-4042	conditions	_
22-8	4043-4046	was	_
22-9	4047-4055	randomly	_
22-10	4056-4064	assigned	_
22-11	4065-4071	across	_
22-12	4072-4080	subjects	_
22-13	4081-4082	(	_
22-14	4083-4089	single	_
22-15	4090-4097	blinded	_
22-16	4098-4099	)	_
22-17	4100-4101	.	_

Text=Subjects drank alcohol (0.75 g/kg mixed in a caffeine-free diet soda) or placebo (caffeine-free diet soda) beverages within a 20 min period under blind conditions.
23-1	4102-4110	Subjects	_
23-2	4111-4116	drank	_
23-3	4117-4124	alcohol	_
23-4	4125-4126	(	_
23-5	4127-4131	0.75	_
23-6	4132-4136	g/kg	_
23-7	4137-4142	mixed	_
23-8	4143-4145	in	_
23-9	4146-4147	a	_
23-10	4148-4161	caffeine-free	_
23-11	4162-4166	diet	_
23-12	4167-4171	soda	_
23-13	4172-4173	)	_
23-14	4174-4176	or	_
23-15	4177-4184	placebo	_
23-16	4185-4186	(	_
23-17	4187-4200	caffeine-free	_
23-18	4201-4205	diet	_
23-19	4206-4210	soda	_
23-20	4211-4212	)	_
23-21	4213-4222	beverages	_
23-22	4223-4229	within	_
23-23	4230-4231	a	_
23-24	4232-4234	20	_
23-25	4235-4238	min	_
23-26	4239-4245	period	_
23-27	4246-4251	under	_
23-28	4252-4257	blind	_
23-29	4258-4268	conditions	_
23-30	4269-4270	.	_

Text=For this purpose, we used a specialized drinking container with an alcohol-containing lid that provided the smell of alcohol and delivered the same volume of liquid in both conditions.
24-1	4271-4274	For	_
24-2	4275-4279	this	_
24-3	4280-4287	purpose	_
24-4	4288-4289	,	_
24-5	4290-4292	we	_
24-6	4293-4297	used	_
24-7	4298-4299	a	_
24-8	4300-4311	specialized	_
24-9	4312-4320	drinking	_
24-10	4321-4330	container	_
24-11	4331-4335	with	_
24-12	4336-4338	an	_
24-13	4339-4357	alcohol-containing	_
24-14	4358-4361	lid	_
24-15	4362-4366	that	_
24-16	4367-4375	provided	_
24-17	4376-4379	the	_
24-18	4380-4385	smell	_
24-19	4386-4388	of	_
24-20	4389-4396	alcohol	_
24-21	4397-4400	and	_
24-22	4401-4410	delivered	_
24-23	4411-4414	the	_
24-24	4415-4419	same	_
24-25	4420-4426	volume	_
24-26	4427-4429	of	_
24-27	4430-4436	liquid	_
24-28	4437-4439	in	_
24-29	4440-4444	both	_
24-30	4445-4455	conditions	_
24-31	4456-4457	.	_

Text=The MRI scan started between 90 and 120 min of ALC or PLC administration.
25-1	4458-4461	The	_
25-2	4462-4465	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
25-3	4466-4470	scan	_
25-4	4471-4478	started	_
25-5	4479-4486	between	_
25-6	4487-4489	90	_
25-7	4490-4493	and	_
25-8	4494-4497	120	_
25-9	4498-4501	min	_
25-10	4502-4504	of	_
25-11	4505-4508	ALC	_
25-12	4509-4511	or	_
25-13	4512-4515	PLC	_
25-14	4516-4530	administration	_
25-15	4531-4532	.	_

Text=The alcohol dose (0.75 g/kg) was approximately equivalent to three drinks for a 50 kg person and was within the range consumed by social drinkers.
26-1	4533-4536	The	_
26-2	4537-4544	alcohol	_
26-3	4545-4549	dose	_
26-4	4550-4551	(	_
26-5	4552-4556	0.75	_
26-6	4557-4561	g/kg	_
26-7	4562-4563	)	_
26-8	4564-4567	was	_
26-9	4568-4581	approximately	_
26-10	4582-4592	equivalent	_
26-11	4593-4595	to	_
26-12	4596-4601	three	_
26-13	4602-4608	drinks	_
26-14	4609-4612	for	_
26-15	4613-4614	a	_
26-16	4615-4617	50	_
26-17	4618-4620	kg	_
26-18	4621-4627	person	_
26-19	4628-4631	and	_
26-20	4632-4635	was	_
26-21	4636-4642	within	_
26-22	4643-4646	the	_
26-23	4647-4652	range	_
26-24	4653-4661	consumed	_
26-25	4662-4664	by	_
26-26	4665-4671	social	_
26-27	4672-4680	drinkers	_
26-28	4681-4682	.	_

Text=Blood alcohol concentration levels were measured prior to the fMRI scan, using a standard enzymatic assay.
27-1	4683-4688	Blood	_
27-2	4689-4696	alcohol	_
27-3	4697-4710	concentration	_
27-4	4711-4717	levels	_
27-5	4718-4722	were	_
27-6	4723-4731	measured	_
27-7	4732-4737	prior	_
27-8	4738-4740	to	_
27-9	4741-4744	the	_
27-10	4745-4749	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
27-11	4750-4754	scan	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
27-12	4755-4756	,	_
27-13	4757-4762	using	_
27-14	4763-4764	a	_
27-15	4765-4773	standard	_
27-16	4774-4783	enzymatic	_
27-17	4784-4789	assay	_
27-18	4790-4791	.	_

Text=The average blood alcohol concentration (BAC) across participants was 0.62 mg/ml (SD = 0.27 mg/ml) at the beginning of the MRI scanning session.
28-1	4792-4795	The	_
28-2	4796-4803	average	_
28-3	4804-4809	blood	_
28-4	4810-4817	alcohol	_
28-5	4818-4831	concentration	_
28-6	4832-4833	(	_
28-7	4834-4837	BAC	_
28-8	4838-4839	)	_
28-9	4840-4846	across	_
28-10	4847-4859	participants	_
28-11	4860-4863	was	_
28-12	4864-4868	0.62	_
28-13	4869-4874	mg/ml	_
28-14	4875-4876	(	_
28-15	4877-4879	SD	_
28-16	4880-4881	=	_
28-17	4882-4886	0.27	_
28-18	4887-4892	mg/ml	_
28-19	4893-4894	)	_
28-20	4895-4897	at	_
28-21	4898-4901	the	_
28-22	4902-4911	beginning	_
28-23	4912-4914	of	_
28-24	4915-4918	the	_
28-25	4919-4922	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
28-26	4923-4931	scanning	_
28-27	4932-4939	session	_
28-28	4940-4941	.	_

Text=Behavioral measures Self-reports of mood and drug effects, motor evaluations, and cognitive tests were performed to assess the effects of alcohol or placebo on behavior in NM and HD.
29-1	4942-4952	Behavioral	_
29-2	4953-4961	measures	_
29-3	4962-4974	Self-reports	_
29-4	4975-4977	of	_
29-5	4978-4982	mood	_
29-6	4983-4986	and	_
29-7	4987-4991	drug	_
29-8	4992-4999	effects	_
29-9	5000-5001	,	_
29-10	5002-5007	motor	_
29-11	5008-5019	evaluations	_
29-12	5020-5021	,	_
29-13	5022-5025	and	_
29-14	5026-5035	cognitive	_
29-15	5036-5041	tests	_
29-16	5042-5046	were	_
29-17	5047-5056	performed	_
29-18	5057-5059	to	_
29-19	5060-5066	assess	_
29-20	5067-5070	the	_
29-21	5071-5078	effects	_
29-22	5079-5081	of	_
29-23	5082-5089	alcohol	_
29-24	5090-5092	or	_
29-25	5093-5100	placebo	_
29-26	5101-5103	on	_
29-27	5104-5112	behavior	_
29-28	5113-5115	in	_
29-29	5116-5118	NM	_
29-30	5119-5122	and	_
29-31	5123-5125	HD	_
29-32	5126-5127	.	_

Text=Measures were obtained prior to each MRI session, approximately 90 min after placebo or alcohol administration (30 min prior to MRI session).
30-1	5128-5136	Measures	_
30-2	5137-5141	were	_
30-3	5142-5150	obtained	_
30-4	5151-5156	prior	_
30-5	5157-5159	to	_
30-6	5160-5164	each	_
30-7	5165-5168	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
30-8	5169-5176	session	_
30-9	5177-5178	,	_
30-10	5179-5192	approximately	_
30-11	5193-5195	90	_
30-12	5196-5199	min	_
30-13	5200-5205	after	_
30-14	5206-5213	placebo	_
30-15	5214-5216	or	_
30-16	5217-5224	alcohol	_
30-17	5225-5239	administration	_
30-18	5240-5241	(	_
30-19	5242-5244	30	_
30-20	5245-5248	min	_
30-21	5249-5254	prior	_
30-22	5255-5257	to	_
30-23	5258-5261	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
30-24	5262-5269	session	_
30-25	5270-5271	)	_
30-26	5272-5273	.	_

Text=Self-report mood/drug effects were scored by the subject from 0 (not at all) to 10 (extremely) for feelings of stimulated, sedated, self-confident, social, irritable, dizzy, high, anxious, pleasant, alcohol desire, control, intoxicated, and restless.
31-1	5274-5285	Self-report	_
31-2	5286-5295	mood/drug	_
31-3	5296-5303	effects	_
31-4	5304-5308	were	_
31-5	5309-5315	scored	_
31-6	5316-5318	by	_
31-7	5319-5322	the	_
31-8	5323-5330	subject	_
31-9	5331-5335	from	_
31-10	5336-5337	0	_
31-11	5338-5339	(	_
31-12	5340-5343	not	_
31-13	5344-5346	at	_
31-14	5347-5350	all	_
31-15	5351-5352	)	_
31-16	5353-5355	to	_
31-17	5356-5358	10	_
31-18	5359-5360	(	_
31-19	5361-5370	extremely	_
31-20	5371-5372	)	_
31-21	5373-5376	for	_
31-22	5377-5385	feelings	_
31-23	5386-5388	of	_
31-24	5389-5399	stimulated	_
31-25	5400-5401	,	_
31-26	5402-5409	sedated	_
31-27	5410-5411	,	_
31-28	5412-5426	self-confident	_
31-29	5427-5428	,	_
31-30	5429-5435	social	_
31-31	5436-5437	,	_
31-32	5438-5447	irritable	_
31-33	5448-5449	,	_
31-34	5450-5455	dizzy	_
31-35	5456-5457	,	_
31-36	5458-5462	high	_
31-37	5463-5464	,	_
31-38	5465-5472	anxious	_
31-39	5473-5474	,	_
31-40	5475-5483	pleasant	_
31-41	5484-5485	,	_
31-42	5486-5493	alcohol	_
31-43	5494-5500	desire	_
31-44	5501-5502	,	_
31-45	5503-5510	control	_
31-46	5511-5512	,	_
31-47	5513-5524	intoxicated	_
31-48	5525-5526	,	_
31-49	5527-5530	and	_
31-50	5531-5539	restless	_
31-51	5540-5541	.	_

Text=Motor function evaluated gait (time and errors), standing on one leg (errors), Romberg (time and errors), and rhythm (time and errors) tasks.
32-1	5542-5547	Motor	_
32-2	5548-5556	function	_
32-3	5557-5566	evaluated	_
32-4	5567-5571	gait	_
32-5	5572-5573	(	_
32-6	5574-5578	time	_
32-7	5579-5582	and	_
32-8	5583-5589	errors	_
32-9	5590-5591	)	_
32-10	5592-5593	,	_
32-11	5594-5602	standing	_
32-12	5603-5605	on	_
32-13	5606-5609	one	_
32-14	5610-5613	leg	_
32-15	5614-5615	(	_
32-16	5616-5622	errors	_
32-17	5623-5624	)	_
32-18	5625-5626	,	_
32-19	5627-5634	Romberg	_
32-20	5635-5636	(	_
32-21	5637-5641	time	_
32-22	5642-5645	and	_
32-23	5646-5652	errors	_
32-24	5653-5654	)	_
32-25	5655-5656	,	_
32-26	5657-5660	and	_
32-27	5661-5667	rhythm	_
32-28	5668-5669	(	_
32-29	5670-5674	time	_
32-30	5675-5678	and	_
32-31	5679-5685	errors	_
32-32	5686-5687	)	_
32-33	5688-5693	tasks	_
32-34	5694-5695	.	_

Text=Cognitive evaluation was made by staff credentialed to perform psychological assessments and included the Stroop (neutral, congruent, and incongruent), Symbol Digit Modalities test (SDMT), and Word Association tasks.
33-1	5696-5705	Cognitive	_
33-2	5706-5716	evaluation	_
33-3	5717-5720	was	_
33-4	5721-5725	made	_
33-5	5726-5728	by	_
33-6	5729-5734	staff	_
33-7	5735-5747	credentialed	_
33-8	5748-5750	to	_
33-9	5751-5758	perform	_
33-10	5759-5772	psychological	_
33-11	5773-5784	assessments	_
33-12	5785-5788	and	_
33-13	5789-5797	included	_
33-14	5798-5801	the	_
33-15	5802-5808	Stroop	_
33-16	5809-5810	(	_
33-17	5811-5818	neutral	_
33-18	5819-5820	,	_
33-19	5821-5830	congruent	_
33-20	5831-5832	,	_
33-21	5833-5836	and	_
33-22	5837-5848	incongruent	_
33-23	5849-5850	)	_
33-24	5851-5852	,	_
33-25	5853-5859	Symbol	_
33-26	5860-5865	Digit	_
33-27	5866-5876	Modalities	_
33-28	5877-5881	test	_
33-29	5882-5883	(	_
33-30	5884-5888	SDMT	_
33-31	5889-5890	)	_
33-32	5891-5892	,	_
33-33	5893-5896	and	_
33-34	5897-5901	Word	_
33-35	5902-5913	Association	_
33-36	5914-5919	tasks	_
33-37	5920-5921	.	_

Text=Behavioral data on two subjects (one NM and one HD) were not available.
34-1	5922-5932	Behavioral	_
34-2	5933-5937	data	_
34-3	5938-5940	on	_
34-4	5941-5944	two	_
34-5	5945-5953	subjects	_
34-6	5954-5955	(	_
34-7	5956-5959	one	_
34-8	5960-5962	NM	_
34-9	5963-5966	and	_
34-10	5967-5970	one	_
34-11	5971-5973	HD	_
34-12	5974-5975	)	_
34-13	5976-5980	were	_
34-14	5981-5984	not	_
34-15	5985-5994	available	_
34-16	5995-5996	.	_

Text=The between-subject factor of Groups and within-subject factor of Alcohol were modelled in MATLAB (The MathWorks Inc., Natick, MA) while using smoking history and gender as covariates.
35-1	5997-6000	The	_
35-2	6001-6016	between-subject	_
35-3	6017-6023	factor	_
35-4	6024-6026	of	_
35-5	6027-6033	Groups	_
35-6	6034-6037	and	_
35-7	6038-6052	within-subject	_
35-8	6053-6059	factor	_
35-9	6060-6062	of	_
35-10	6063-6070	Alcohol	_
35-11	6071-6075	were	_
35-12	6076-6084	modelled	_
35-13	6085-6087	in	_
35-14	6088-6094	MATLAB	_
35-15	6095-6096	(	_
35-16	6097-6100	The	_
35-17	6101-6110	MathWorks	_
35-18	6111-6115	Inc.	_
35-19	6116-6117	,	_
35-20	6118-6124	Natick	_
35-21	6125-6126	,	_
35-22	6127-6129	MA	_
35-23	6130-6131	)	_
35-24	6132-6137	while	_
35-25	6138-6143	using	_
35-26	6144-6151	smoking	_
35-27	6152-6159	history	_
35-28	6160-6163	and	_
35-29	6164-6170	gender	_
35-30	6171-6173	as	_
35-31	6174-6184	covariates	_
35-32	6185-6186	.	_

Text=We minimized multiplicity of comparisons by grouping the behavioral measures into three categories: mood and drug effects, motor, and cognitive performance (see partial least squares regression for further information).
36-1	6187-6189	We	_
36-2	6190-6199	minimized	_
36-3	6200-6212	multiplicity	_
36-4	6213-6215	of	_
36-5	6216-6227	comparisons	_
36-6	6228-6230	by	_
36-7	6231-6239	grouping	_
36-8	6240-6243	the	_
36-9	6244-6254	behavioral	_
36-10	6255-6263	measures	_
36-11	6264-6268	into	_
36-12	6269-6274	three	_
36-13	6275-6285	categories	_
36-14	6286-6287	:	_
36-15	6288-6292	mood	_
36-16	6293-6296	and	_
36-17	6297-6301	drug	_
36-18	6302-6309	effects	_
36-19	6310-6311	,	_
36-20	6312-6317	motor	_
36-21	6318-6319	,	_
36-22	6320-6323	and	_
36-23	6324-6333	cognitive	_
36-24	6334-6345	performance	_
36-25	6346-6347	(	_
36-26	6348-6351	see	_
36-27	6352-6359	partial	_
36-28	6360-6365	least	_
36-29	6366-6373	squares	_
36-30	6374-6384	regression	_
36-31	6385-6388	for	_
36-32	6389-6396	further	_
36-33	6397-6408	information	_
36-34	6409-6410	)	_
36-35	6411-6412	.	_

Text=MRI data acquisition Subjects underwent fMRI in a 4-tesla Varian/Siemens MRI scanner (Siemens Medical Solutions, Erlangen, Germany) using a T2 * -weighted single-shot gradient-echo planar imaging sequence (echo time/repetition time, 20/1600 ms; 4-mm slice thickness; 1-mm gap; 33 coronal slices; 3.1 × 3.1 mm in-plane resolution).
37-1	6413-6416	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
37-2	6417-6421	data	_
37-3	6422-6433	acquisition	_
37-4	6434-6442	Subjects	_
37-5	6443-6452	underwent	_
37-6	6453-6457	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
37-7	6458-6460	in	_
37-8	6461-6462	a	_
37-9	6463-6470	4-tesla	_
37-10	6471-6485	Varian/Siemens	_
37-11	6486-6489	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
37-12	6490-6497	scanner	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
37-13	6498-6499	(	_
37-14	6500-6507	Siemens	_
37-15	6508-6515	Medical	_
37-16	6516-6525	Solutions	_
37-17	6526-6527	,	_
37-18	6528-6536	Erlangen	_
37-19	6537-6538	,	_
37-20	6539-6546	Germany	_
37-21	6547-6548	)	_
37-22	6549-6554	using	_
37-23	6555-6556	a	_
37-24	6557-6559	T2	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
37-25	6560-6561	*	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
37-26	6562-6571	-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
37-27	6572-6583	single-shot	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
37-28	6584-6597	gradient-echo	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
37-29	6598-6604	planar	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
37-30	6605-6612	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
37-31	6613-6621	sequence	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
37-32	6622-6623	(	_
37-33	6624-6628	echo	_
37-34	6629-6644	time/repetition	_
37-35	6645-6649	time	_
37-36	6650-6651	,	_
37-37	6652-6659	20/1600	_
37-38	6660-6662	ms	_
37-39	6663-6664	;	_
37-40	6665-6669	4-mm	_
37-41	6670-6675	slice	_
37-42	6676-6685	thickness	_
37-43	6686-6687	;	_
37-44	6688-6692	1-mm	_
37-45	6693-6696	gap	_
37-46	6697-6698	;	_
37-47	6699-6701	33	_
37-48	6702-6709	coronal	_
37-49	6710-6716	slices	_
37-50	6717-6718	;	_
37-51	6719-6722	3.1	_
37-52	6723-6724	×	_
37-53	6725-6728	3.1	_
37-54	6729-6731	mm	_
37-55	6732-6740	in-plane	_
37-56	6741-6751	resolution	_
37-57	6752-6753	)	_
37-58	6754-6755	.	_

Text=Participants were instructed to remain silent, motionless, and awake with eyes open during the 5-min resting-state scan with presentation of a fixation cross.
38-1	6756-6768	Participants	_
38-2	6769-6773	were	_
38-3	6774-6784	instructed	_
38-4	6785-6787	to	_
38-5	6788-6794	remain	_
38-6	6795-6801	silent	_
38-7	6802-6803	,	_
38-8	6804-6814	motionless	_
38-9	6815-6816	,	_
38-10	6817-6820	and	_
38-11	6821-6826	awake	_
38-12	6827-6831	with	_
38-13	6832-6836	eyes	_
38-14	6837-6841	open	_
38-15	6842-6848	during	_
38-16	6849-6852	the	_
38-17	6853-6858	5-min	_
38-18	6859-6872	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
38-19	6873-6877	scan	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
38-20	6878-6882	with	_
38-21	6883-6895	presentation	_
38-22	6896-6898	of	_
38-23	6899-6900	a	_
38-24	6901-6909	fixation	_
38-25	6910-6915	cross	_
38-26	6916-6917	.	_

Text=fMRI data preprocessing All fMRI time series were realigned and normalized to the Montreal Neurological Institute (MNI) space with 3-mm isotropic voxels in SPM8 (Wellcome Trust Centre for Neuroimaging, London).
39-1	6918-6922	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
39-2	6923-6927	data	_
39-3	6928-6941	preprocessing	_
39-4	6942-6945	All	_
39-5	6946-6950	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
39-6	6951-6955	time	_
39-7	6956-6962	series	_
39-8	6963-6967	were	_
39-9	6968-6977	realigned	_
39-10	6978-6981	and	_
39-11	6982-6992	normalized	_
39-12	6993-6995	to	_
39-13	6996-6999	the	_
39-14	7000-7008	Montreal	_
39-15	7009-7021	Neurological	_
39-16	7022-7031	Institute	_
39-17	7032-7033	(	_
39-18	7034-7037	MNI	_
39-19	7038-7039	)	_
39-20	7040-7045	space	_
39-21	7046-7050	with	_
39-22	7051-7055	3-mm	_
39-23	7056-7065	isotropic	_
39-24	7066-7072	voxels	_
39-25	7073-7075	in	_
39-26	7076-7080	SPM8	_
39-27	7081-7082	(	_
39-28	7083-7091	Wellcome	_
39-29	7092-7097	Trust	_
39-30	7098-7104	Centre	_
39-31	7105-7108	for	_
39-32	7109-7121	Neuroimaging	_
39-33	7122-7123	,	_
39-34	7124-7130	London	_
39-35	7131-7132	)	_
39-36	7133-7134	.	_

Text=There were no significant main effects of Group or Alcohol, or a significant interaction effect on estimates of subjects ’ motion (p> 0.05) for mean frame-wise displacement calculated from 6 translation and rotation parameters obtained from the realignment process.
40-1	7135-7140	There	_
40-2	7141-7145	were	_
40-3	7146-7148	no	_
40-4	7149-7160	significant	_
40-5	7161-7165	main	_
40-6	7166-7173	effects	_
40-7	7174-7176	of	_
40-8	7177-7182	Group	_
40-9	7183-7185	or	_
40-10	7186-7193	Alcohol	_
40-11	7194-7195	,	_
40-12	7196-7198	or	_
40-13	7199-7200	a	_
40-14	7201-7212	significant	_
40-15	7213-7224	interaction	_
40-16	7225-7231	effect	_
40-17	7232-7234	on	_
40-18	7235-7244	estimates	_
40-19	7245-7247	of	_
40-20	7248-7256	subjects	_
40-21	7257-7258	’	_
40-22	7259-7265	motion	_
40-23	7266-7267	(	_
40-24	7268-7269	p	_
40-25	7270-7271	>	_
40-26	7272-7276	0.05	_
40-27	7277-7278	)	_
40-28	7279-7282	for	_
40-29	7283-7287	mean	_
40-30	7288-7298	frame-wise	_
40-31	7299-7311	displacement	_
40-32	7312-7322	calculated	_
40-33	7323-7327	from	_
40-34	7328-7329	6	_
40-35	7330-7341	translation	_
40-36	7342-7345	and	_
40-37	7346-7354	rotation	_
40-38	7355-7365	parameters	_
40-39	7366-7374	obtained	_
40-40	7375-7379	from	_
40-41	7380-7383	the	_
40-42	7384-7395	realignment	_
40-43	7396-7403	process	_
40-44	7404-7405	.	_

Text=FMRI time points that were severely affected by motion were removed using a “ scrubbing ” approach.
41-1	7406-7410	FMRI	_
41-2	7411-7415	time	_
41-3	7416-7422	points	_
41-4	7423-7427	that	_
41-5	7428-7432	were	_
41-6	7433-7441	severely	_
41-7	7442-7450	affected	_
41-8	7451-7453	by	_
41-9	7454-7460	motion	_
41-10	7461-7465	were	_
41-11	7466-7473	removed	_
41-12	7474-7479	using	_
41-13	7480-7481	a	_
41-14	7482-7483	“	_
41-15	7484-7493	scrubbing	_
41-16	7494-7495	”	_
41-17	7496-7504	approach	_
41-18	7505-7506	.	_

Text=Specifically, in each subject/session, less than 4% of time-points were removed with a root mean square signal change (that is, DVARs) threshold of 5% and a framewise displacement (that is, FD) threshold of 0.5 mm.
42-1	7507-7519	Specifically	_
42-2	7520-7521	,	_
42-3	7522-7524	in	_
42-4	7525-7529	each	_
42-5	7530-7545	subject/session	_
42-6	7546-7547	,	_
42-7	7548-7552	less	_
42-8	7553-7557	than	_
42-9	7558-7559	4	_
42-10	7560-7561	%	_
42-11	7562-7564	of	_
42-12	7565-7576	time-points	_
42-13	7577-7581	were	_
42-14	7582-7589	removed	_
42-15	7590-7594	with	_
42-16	7595-7596	a	_
42-17	7597-7601	root	_
42-18	7602-7606	mean	_
42-19	7607-7613	square	_
42-20	7614-7620	signal	_
42-21	7621-7627	change	_
42-22	7628-7629	(	_
42-23	7630-7634	that	_
42-24	7635-7637	is	_
42-25	7638-7639	,	_
42-26	7640-7645	DVARs	_
42-27	7646-7647	)	_
42-28	7648-7657	threshold	_
42-29	7658-7660	of	_
42-30	7661-7662	5	_
42-31	7663-7664	%	_
42-32	7665-7668	and	_
42-33	7669-7670	a	_
42-34	7671-7680	framewise	_
42-35	7681-7693	displacement	_
42-36	7694-7695	(	_
42-37	7696-7700	that	_
42-38	7701-7703	is	_
42-39	7704-7705	,	_
42-40	7706-7708	FD	_
42-41	7709-7710	)	_
42-42	7711-7720	threshold	_
42-43	7721-7723	of	_
42-44	7724-7727	0.5	_
42-45	7728-7730	mm	_
42-46	7731-7732	.	_

Text=Remaining motion effects on fMRI time series were regressed out using the 6 translation and rotation regressors.
43-1	7733-7742	Remaining	_
43-2	7743-7749	motion	_
43-3	7750-7757	effects	_
43-4	7758-7760	on	_
43-5	7761-7765	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
43-6	7766-7770	time	_
43-7	7771-7777	series	_
43-8	7778-7782	were	_
43-9	7783-7792	regressed	_
43-10	7793-7796	out	_
43-11	7797-7802	using	_
43-12	7803-7806	the	_
43-13	7807-7808	6	_
43-14	7809-7820	translation	_
43-15	7821-7824	and	_
43-16	7825-7833	rotation	_
43-17	7834-7844	regressors	_
43-18	7845-7846	.	_

Text=Voxels with poor temporal signal-to-noise (tSNR <50) were eliminated, and band-pass temporal filtering (0.01–0.10 Hz) was used to remove magnetic field drifts of the scanner and to minimize the effects of physiologic noise on the high-frequency components.
44-1	7847-7853	Voxels	_
44-2	7854-7858	with	_
44-3	7859-7863	poor	_
44-4	7864-7872	temporal	_
44-5	7873-7888	signal-to-noise	_
44-6	7889-7890	(	_
44-7	7891-7895	tSNR	_
44-8	7896-7897	<	_
44-9	7898-7900	50	_
44-10	7901-7902	)	_
44-11	7903-7907	were	_
44-12	7908-7918	eliminated	_
44-13	7919-7920	,	_
44-14	7921-7924	and	_
44-15	7925-7934	band-pass	_
44-16	7935-7943	temporal	_
44-17	7944-7953	filtering	_
44-18	7954-7955	(	_
44-19	7956-7965	0.01–0.10	_
44-20	7966-7968	Hz	_
44-21	7969-7970	)	_
44-22	7971-7974	was	_
44-23	7975-7979	used	_
44-24	7980-7982	to	_
44-25	7983-7989	remove	_
44-26	7990-7998	magnetic	_
44-27	7999-8004	field	_
44-28	8005-8011	drifts	_
44-29	8012-8014	of	_
44-30	8015-8018	the	_
44-31	8019-8026	scanner	_
44-32	8027-8030	and	_
44-33	8031-8033	to	_
44-34	8034-8042	minimize	_
44-35	8043-8046	the	_
44-36	8047-8054	effects	_
44-37	8055-8057	of	_
44-38	8058-8069	physiologic	_
44-39	8070-8075	noise	_
44-40	8076-8078	on	_
44-41	8079-8082	the	_
44-42	8083-8097	high-frequency	_
44-43	8098-8108	components	_
44-44	8109-8110	.	_

Text=The effects of unwanted fluctuations within the white matter and cerebrospinal fluid (CSF) were excluded from the analysis by using a gray matter mask (N = 57,713).
45-1	8111-8114	The	_
45-2	8115-8122	effects	_
45-3	8123-8125	of	_
45-4	8126-8134	unwanted	_
45-5	8135-8147	fluctuations	_
45-6	8148-8154	within	_
45-7	8155-8158	the	_
45-8	8159-8164	white	_
45-9	8165-8171	matter	_
45-10	8172-8175	and	_
45-11	8176-8189	cerebrospinal	_
45-12	8190-8195	fluid	_
45-13	8196-8197	(	_
45-14	8198-8201	CSF	_
45-15	8202-8203	)	_
45-16	8204-8208	were	_
45-17	8209-8217	excluded	_
45-18	8218-8222	from	_
45-19	8223-8226	the	_
45-20	8227-8235	analysis	_
45-21	8236-8238	by	_
45-22	8239-8244	using	_
45-23	8245-8246	a	_
45-24	8247-8251	gray	_
45-25	8252-8258	matter	_
45-26	8259-8263	mask	_
45-27	8264-8265	(	_
45-28	8266-8267	N	_
45-29	8268-8269	=	_
45-30	8270-8276	57,713	_
45-31	8277-8278	)	_
45-32	8279-8280	.	_

Text=Local functional connectivity density (lFCD) The Pearson correlation was used to assess the strength of functional connectivity, Cij, between voxels i and j.
46-1	8281-8286	Local	_
46-2	8287-8297	functional	_
46-3	8298-8310	connectivity	_
46-4	8311-8318	density	_
46-5	8319-8320	(	_
46-6	8321-8325	lFCD	_
46-7	8326-8327	)	_
46-8	8328-8331	The	_
46-9	8332-8339	Pearson	_
46-10	8340-8351	correlation	_
46-11	8352-8355	was	_
46-12	8356-8360	used	_
46-13	8361-8363	to	_
46-14	8364-8370	assess	_
46-15	8371-8374	the	_
46-16	8375-8383	strength	_
46-17	8384-8386	of	_
46-18	8387-8397	functional	_
46-19	8398-8410	connectivity	_
46-20	8411-8412	,	_
46-21	8413-8416	Cij	_
46-22	8417-8418	,	_
46-23	8419-8426	between	_
46-24	8427-8433	voxels	_
46-25	8434-8435	i	_
46-26	8436-8439	and	_
46-27	8440-8441	j	_
46-28	8442-8443	.	_

Text=Consistent with prior FCD studies, a positive correlation threshold of r = 0.6 (sufficient to Bonferroni correct for the number of correlations performed in the whole brain, p <0.05) was used to compute the binary connectivity coefficients, aij = 1 (if Cij> 0.6) or aij = 0 (if Cij ≤ 0.6).
47-1	8444-8454	Consistent	_
47-2	8455-8459	with	_
47-3	8460-8465	prior	_
47-4	8466-8469	FCD	_
47-5	8470-8477	studies	_
47-6	8478-8479	,	_
47-7	8480-8481	a	_
47-8	8482-8490	positive	_
47-9	8491-8502	correlation	_
47-10	8503-8512	threshold	_
47-11	8513-8515	of	_
47-12	8516-8517	r	_
47-13	8518-8519	=	_
47-14	8520-8523	0.6	_
47-15	8524-8525	(	_
47-16	8526-8536	sufficient	_
47-17	8537-8539	to	_
47-18	8540-8550	Bonferroni	_
47-19	8551-8558	correct	_
47-20	8559-8562	for	_
47-21	8563-8566	the	_
47-22	8567-8573	number	_
47-23	8574-8576	of	_
47-24	8577-8589	correlations	_
47-25	8590-8599	performed	_
47-26	8600-8602	in	_
47-27	8603-8606	the	_
47-28	8607-8612	whole	_
47-29	8613-8618	brain	_
47-30	8619-8620	,	_
47-31	8621-8622	p	_
47-32	8623-8624	<	_
47-33	8625-8629	0.05	_
47-34	8630-8631	)	_
47-35	8632-8635	was	_
47-36	8636-8640	used	_
47-37	8641-8643	to	_
47-38	8644-8651	compute	_
47-39	8652-8655	the	_
47-40	8656-8662	binary	_
47-41	8663-8675	connectivity	_
47-42	8676-8688	coefficients	_
47-43	8689-8690	,	_
47-44	8691-8694	aij	_
47-45	8695-8696	=	_
47-46	8697-8698	1	_
47-47	8699-8700	(	_
47-48	8701-8703	if	_
47-49	8704-8707	Cij	_
47-50	8708-8709	>	_
47-51	8710-8713	0.6	_
47-52	8714-8715	)	_
47-53	8716-8718	or	_
47-54	8719-8722	aij	_
47-55	8723-8724	=	_
47-56	8725-8726	0	_
47-57	8727-8728	(	_
47-58	8729-8731	if	_
47-59	8732-8735	Cij	_
47-60	8736-8737	≤	_
47-61	8738-8741	0.6	_
47-62	8742-8743	)	_
47-63	8744-8745	.	_

Text=The local functional connectivity density (or “ local degree ”) for voxel i was computed as the size of a continuous cluster of voxels with aij = 1, that are connected by surface.
48-1	8746-8749	The	_
48-2	8750-8755	local	_
48-3	8756-8766	functional	_
48-4	8767-8779	connectivity	_
48-5	8780-8787	density	_
48-6	8788-8789	(	_
48-7	8790-8792	or	_
48-8	8793-8794	“	_
48-9	8795-8800	local	_
48-10	8801-8807	degree	_
48-11	8808-8809	”	_
48-12	8810-8811	)	_
48-13	8812-8815	for	_
48-14	8816-8821	voxel	_
48-15	8822-8823	i	_
48-16	8824-8827	was	_
48-17	8828-8836	computed	_
48-18	8837-8839	as	_
48-19	8840-8843	the	_
48-20	8844-8848	size	_
48-21	8849-8851	of	_
48-22	8852-8853	a	_
48-23	8854-8864	continuous	_
48-24	8865-8872	cluster	_
48-25	8873-8875	of	_
48-26	8876-8882	voxels	_
48-27	8883-8887	with	_
48-28	8888-8891	aij	_
48-29	8892-8893	=	_
48-30	8894-8895	1	_
48-31	8896-8897	,	_
48-32	8898-8902	that	_
48-33	8903-8906	are	_
48-34	8907-8916	connected	_
48-35	8917-8919	by	_
48-36	8920-8927	surface	_
48-37	8928-8929	.	_

Text=A “ growing ” algorithm was used for time efficient estimation of lFCD.
49-1	8930-8931	A	_
49-2	8932-8933	“	_
49-3	8934-8941	growing	_
49-4	8942-8943	”	_
49-5	8944-8953	algorithm	_
49-6	8954-8957	was	_
49-7	8958-8962	used	_
49-8	8963-8966	for	_
49-9	8967-8971	time	_
49-10	8972-8981	efficient	_
49-11	8982-8992	estimation	_
49-12	8993-8995	of	_
49-13	8996-9000	lFCD	_
49-14	9001-9002	.	_

Text=Global functional connectivity density (gFCD) The gFCD, also called “ degree ” was calculated as the total number of edges for voxel i, i.e., significant correlations (at Cij> 0.6) between voxel i and all voxels: Statistical parametric mapping (SPM) SPM8 was used to perform voxel-wise analyses on FCD indices.
50-1	9003-9009	Global	_
50-2	9010-9020	functional	_
50-3	9021-9033	connectivity	_
50-4	9034-9041	density	_
50-5	9042-9043	(	_
50-6	9044-9048	gFCD	_
50-7	9049-9050	)	_
50-8	9051-9054	The	_
50-9	9055-9059	gFCD	_
50-10	9060-9061	,	_
50-11	9062-9066	also	_
50-12	9067-9073	called	_
50-13	9074-9075	“	_
50-14	9076-9082	degree	_
50-15	9083-9084	”	_
50-16	9085-9088	was	_
50-17	9089-9099	calculated	_
50-18	9100-9102	as	_
50-19	9103-9106	the	_
50-20	9107-9112	total	_
50-21	9113-9119	number	_
50-22	9120-9122	of	_
50-23	9123-9128	edges	_
50-24	9129-9132	for	_
50-25	9133-9138	voxel	_
50-26	9139-9140	i	_
50-27	9141-9142	,	_
50-28	9143-9147	i.e.	_
50-29	9148-9149	,	_
50-30	9150-9161	significant	_
50-31	9162-9174	correlations	_
50-32	9175-9176	(	_
50-33	9177-9179	at	_
50-34	9180-9183	Cij	_
50-35	9184-9185	>	_
50-36	9186-9189	0.6	_
50-37	9190-9191	)	_
50-38	9192-9199	between	_
50-39	9200-9205	voxel	_
50-40	9206-9207	i	_
50-41	9208-9211	and	_
50-42	9212-9215	all	_
50-43	9216-9222	voxels	_
50-44	9223-9224	:	_
50-45	9225-9236	Statistical	_
50-46	9237-9247	parametric	_
50-47	9248-9255	mapping	_
50-48	9256-9257	(	_
50-49	9258-9261	SPM	_
50-50	9262-9263	)	_
50-51	9264-9268	SPM8	_
50-52	9269-9272	was	_
50-53	9273-9277	used	_
50-54	9278-9280	to	_
50-55	9281-9288	perform	_
50-56	9289-9299	voxel-wise	_
50-57	9300-9308	analyses	_
50-58	9309-9311	on	_
50-59	9312-9315	FCD	_
50-60	9316-9323	indices	_
50-61	9324-9325	.	_

Text=Gender and smoking status were entered as covariates to control for differences between the groups in these variables.
51-1	9326-9332	Gender	_
51-2	9333-9336	and	_
51-3	9337-9344	smoking	_
51-4	9345-9351	status	_
51-5	9352-9356	were	_
51-6	9357-9364	entered	_
51-7	9365-9367	as	_
51-8	9368-9378	covariates	_
51-9	9379-9381	to	_
51-10	9382-9389	control	_
51-11	9390-9393	for	_
51-12	9394-9405	differences	_
51-13	9406-9413	between	_
51-14	9414-9417	the	_
51-15	9418-9424	groups	_
51-16	9425-9427	in	_
51-17	9428-9433	these	_
51-18	9434-9443	variables	_
51-19	9444-9445	.	_

Text=A flexible factorial design was used to model the between-subject factor of Group (NM vs. HD) and the within-subject factor of Alcohol (PLC and ALC).
52-1	9446-9447	A	_
52-2	9448-9456	flexible	_
52-3	9457-9466	factorial	_
52-4	9467-9473	design	_
52-5	9474-9477	was	_
52-6	9478-9482	used	_
52-7	9483-9485	to	_
52-8	9486-9491	model	_
52-9	9492-9495	the	_
52-10	9496-9511	between-subject	_
52-11	9512-9518	factor	_
52-12	9519-9521	of	_
52-13	9522-9527	Group	_
52-14	9528-9529	(	_
52-15	9530-9532	NM	_
52-16	9533-9536	vs.	_
52-17	9537-9539	HD	_
52-18	9540-9541	)	_
52-19	9542-9545	and	_
52-20	9546-9549	the	_
52-21	9550-9564	within-subject	_
52-22	9565-9571	factor	_
52-23	9572-9574	of	_
52-24	9575-9582	Alcohol	_
52-25	9583-9584	(	_
52-26	9585-9588	PLC	_
52-27	9589-9592	and	_
52-28	9593-9596	ALC	_
52-29	9597-9598	)	_
52-30	9599-9600	.	_

Text=Regions of interest (ROIs) were identified after family wise error (FWE) correction for multiple comparisons at the cluster level correction approach (pFWE <0.05) with a minimum cluster size of k = 75 and a cluster forming threshold of p <0.005.
53-1	9601-9608	Regions	_
53-2	9609-9611	of	_
53-3	9612-9620	interest	_
53-4	9621-9622	(	_
53-5	9623-9627	ROIs	_
53-6	9628-9629	)	_
53-7	9630-9634	were	_
53-8	9635-9645	identified	_
53-9	9646-9651	after	_
53-10	9652-9658	family	_
53-11	9659-9663	wise	_
53-12	9664-9669	error	_
53-13	9670-9671	(	_
53-14	9672-9675	FWE	_
53-15	9676-9677	)	_
53-16	9678-9688	correction	_
53-17	9689-9692	for	_
53-18	9693-9701	multiple	_
53-19	9702-9713	comparisons	_
53-20	9714-9716	at	_
53-21	9717-9720	the	_
53-22	9721-9728	cluster	_
53-23	9729-9734	level	_
53-24	9735-9745	correction	_
53-25	9746-9754	approach	_
53-26	9755-9756	(	_
53-27	9757-9761	pFWE	_
53-28	9762-9763	<	_
53-29	9764-9768	0.05	_
53-30	9769-9770	)	_
53-31	9771-9775	with	_
53-32	9776-9777	a	_
53-33	9778-9785	minimum	_
53-34	9786-9793	cluster	_
53-35	9794-9798	size	_
53-36	9799-9801	of	_
53-37	9802-9803	k	_
53-38	9804-9805	=	_
53-39	9806-9808	75	_
53-40	9809-9812	and	_
53-41	9813-9814	a	_
53-42	9815-9822	cluster	_
53-43	9823-9830	forming	_
53-44	9831-9840	threshold	_
53-45	9841-9843	of	_
53-46	9844-9845	p	_
53-47	9846-9847	<	_
53-48	9848-9853	0.005	_
53-49	9854-9855	.	_

Text=Neurocognitive coupling analysis We define ‘ neurocognitive coupling ’ as the overall association between individual differences in regional resting activity (indexed here by ROI FCD) and individual differences in behavioral performance.
54-1	9856-9870	Neurocognitive	_
54-2	9871-9879	coupling	_
54-3	9880-9888	analysis	_
54-4	9889-9891	We	_
54-5	9892-9898	define	_
54-6	9899-9900	‘	_
54-7	9901-9915	neurocognitive	_
54-8	9916-9924	coupling	_
54-9	9925-9926	’	_
54-10	9927-9929	as	_
54-11	9930-9933	the	_
54-12	9934-9941	overall	_
54-13	9942-9953	association	_
54-14	9954-9961	between	_
54-15	9962-9972	individual	_
54-16	9973-9984	differences	_
54-17	9985-9987	in	_
54-18	9988-9996	regional	_
54-19	9997-10004	resting	_
54-20	10005-10013	activity	_
54-21	10014-10015	(	_
54-22	10016-10023	indexed	_
54-23	10024-10028	here	_
54-24	10029-10031	by	_
54-25	10032-10035	ROI	_
54-26	10036-10039	FCD	_
54-27	10040-10041	)	_
54-28	10042-10045	and	_
54-29	10046-10056	individual	_
54-30	10057-10068	differences	_
54-31	10069-10071	in	_
54-32	10072-10082	behavioral	_
54-33	10083-10094	performance	_
54-34	10095-10096	.	_

Text=Specifically, a two-way repeated measures ANOVA was performed in MATLAB to assess effects of Group and Alcohol on the distribution mean of Fisher ’ s z-transformed correlations between functional ROIs that showed Group or Alcohol effects and behavioral measures that showed Group or Alcohol effects.
55-1	10097-10109	Specifically	_
55-2	10110-10111	,	_
55-3	10112-10113	a	_
55-4	10114-10121	two-way	_
55-5	10122-10130	repeated	_
55-6	10131-10139	measures	_
55-7	10140-10145	ANOVA	_
55-8	10146-10149	was	_
55-9	10150-10159	performed	_
55-10	10160-10162	in	_
55-11	10163-10169	MATLAB	_
55-12	10170-10172	to	_
55-13	10173-10179	assess	_
55-14	10180-10187	effects	_
55-15	10188-10190	of	_
55-16	10191-10196	Group	_
55-17	10197-10200	and	_
55-18	10201-10208	Alcohol	_
55-19	10209-10211	on	_
55-20	10212-10215	the	_
55-21	10216-10228	distribution	_
55-22	10229-10233	mean	_
55-23	10234-10236	of	_
55-24	10237-10243	Fisher	_
55-25	10244-10245	’	_
55-26	10246-10247	s	_
55-27	10248-10261	z-transformed	_
55-28	10262-10274	correlations	_
55-29	10275-10282	between	_
55-30	10283-10293	functional	_
55-31	10294-10298	ROIs	_
55-32	10299-10303	that	_
55-33	10304-10310	showed	_
55-34	10311-10316	Group	_
55-35	10317-10319	or	_
55-36	10320-10327	Alcohol	_
55-37	10328-10335	effects	_
55-38	10336-10339	and	_
55-39	10340-10350	behavioral	_
55-40	10351-10359	measures	_
55-41	10360-10364	that	_
55-42	10365-10371	showed	_
55-43	10372-10377	Group	_
55-44	10378-10380	or	_
55-45	10381-10388	Alcohol	_
55-46	10389-10396	effects	_
55-47	10397-10398	.	_

Text=This analysis was also repeated for a set of a priori anatomical ROIs (Supp.
56-1	10399-10403	This	_
56-2	10404-10412	analysis	_
56-3	10413-10416	was	_
56-4	10417-10421	also	_
56-5	10422-10430	repeated	_
56-6	10431-10434	for	_
56-7	10435-10436	a	_
56-8	10437-10440	set	_
56-9	10441-10443	of	_
56-10	10444-10445	a	_
56-11	10446-10452	priori	_
56-12	10453-10463	anatomical	_
56-13	10464-10468	ROIs	_
56-14	10469-10470	(	_
56-15	10471-10475	Supp	_
56-16	10476-10477	.	_

Text=Fig.
57-1	10478-10481	Fig	_
57-2	10482-10483	.	_

Text=3).
58-1	10484-10485	3	_
58-2	10486-10487	)	_
58-3	10488-10489	.	_

Text=Partial least squares regression A partial least squares (PLS) regression analysis was performed in MATLAB to reduce the dimensionality of data and consequently the number of comparisons.
59-1	10490-10497	Partial	_
59-2	10498-10503	least	_
59-3	10504-10511	squares	_
59-4	10512-10522	regression	_
59-5	10523-10524	A	_
59-6	10525-10532	partial	_
59-7	10533-10538	least	_
59-8	10539-10546	squares	_
59-9	10547-10548	(	_
59-10	10549-10552	PLS	_
59-11	10553-10554	)	_
59-12	10555-10565	regression	_
59-13	10566-10574	analysis	_
59-14	10575-10578	was	_
59-15	10579-10588	performed	_
59-16	10589-10591	in	_
59-17	10592-10598	MATLAB	_
59-18	10599-10601	to	_
59-19	10602-10608	reduce	_
59-20	10609-10612	the	_
59-21	10613-10627	dimensionality	_
59-22	10628-10630	of	_
59-23	10631-10635	data	_
59-24	10636-10639	and	_
59-25	10640-10652	consequently	_
59-26	10653-10656	the	_
59-27	10657-10663	number	_
59-28	10664-10666	of	_
59-29	10667-10678	comparisons	_
59-30	10679-10680	.	_

Text=Whereas, other approaches such as principal component analysis (PCA) find components that maximize the variance within a set of variables, PLS regression finds components in the independent variables based on the criteria of maximizing the amount of variance accounted for in both dependent and independent variables.
60-1	10681-10688	Whereas	_
60-2	10689-10690	,	_
60-3	10691-10696	other	_
60-4	10697-10707	approaches	_
60-5	10708-10712	such	_
60-6	10713-10715	as	_
60-7	10716-10725	principal	_
60-8	10726-10735	component	_
60-9	10736-10744	analysis	_
60-10	10745-10746	(	_
60-11	10747-10750	PCA	_
60-12	10751-10752	)	_
60-13	10753-10757	find	_
60-14	10758-10768	components	_
60-15	10769-10773	that	_
60-16	10774-10782	maximize	_
60-17	10783-10786	the	_
60-18	10787-10795	variance	_
60-19	10796-10802	within	_
60-20	10803-10804	a	_
60-21	10805-10808	set	_
60-22	10809-10811	of	_
60-23	10812-10821	variables	_
60-24	10822-10823	,	_
60-25	10824-10827	PLS	_
60-26	10828-10838	regression	_
60-27	10839-10844	finds	_
60-28	10845-10855	components	_
60-29	10856-10858	in	_
60-30	10859-10862	the	_
60-31	10863-10874	independent	_
60-32	10875-10884	variables	_
60-33	10885-10890	based	_
60-34	10891-10893	on	_
60-35	10894-10897	the	_
60-36	10898-10906	criteria	_
60-37	10907-10909	of	_
60-38	10910-10920	maximizing	_
60-39	10921-10924	the	_
60-40	10925-10931	amount	_
60-41	10932-10934	of	_
60-42	10935-10943	variance	_
60-43	10944-10953	accounted	_
60-44	10954-10957	for	_
60-45	10958-10960	in	_
60-46	10961-10965	both	_
60-47	10966-10975	dependent	_
60-48	10976-10979	and	_
60-49	10980-10991	independent	_
60-50	10992-11001	variables	_
60-51	11002-11003	.	_

Text=For each behavioral category (i.e., mood/drug effects, motor, and cognitive performance), the goal of the PLS regression analysis was to find a linear combination of ROI FCDs (component scores) that maximizes the amount of variance accounted for in the included behavioral tests as well as ROI FCDs.
61-1	11004-11007	For	_
61-2	11008-11012	each	_
61-3	11013-11023	behavioral	_
61-4	11024-11032	category	_
61-5	11033-11034	(	_
61-6	11035-11039	i.e.	_
61-7	11040-11041	,	_
61-8	11042-11051	mood/drug	_
61-9	11052-11059	effects	_
61-10	11060-11061	,	_
61-11	11062-11067	motor	_
61-12	11068-11069	,	_
61-13	11070-11073	and	_
61-14	11074-11083	cognitive	_
61-15	11084-11095	performance	_
61-16	11096-11097	)	_
61-17	11098-11099	,	_
61-18	11100-11103	the	_
61-19	11104-11108	goal	_
61-20	11109-11111	of	_
61-21	11112-11115	the	_
61-22	11116-11119	PLS	_
61-23	11120-11130	regression	_
61-24	11131-11139	analysis	_
61-25	11140-11143	was	_
61-26	11144-11146	to	_
61-27	11147-11151	find	_
61-28	11152-11153	a	_
61-29	11154-11160	linear	_
61-30	11161-11172	combination	_
61-31	11173-11175	of	_
61-32	11176-11179	ROI	_
61-33	11180-11184	FCDs	_
61-34	11185-11186	(	_
61-35	11187-11196	component	_
61-36	11197-11203	scores	_
61-37	11204-11205	)	_
61-38	11206-11210	that	_
61-39	11211-11220	maximizes	_
61-40	11221-11224	the	_
61-41	11225-11231	amount	_
61-42	11232-11234	of	_
61-43	11235-11243	variance	_
61-44	11244-11253	accounted	_
61-45	11254-11257	for	_
61-46	11258-11260	in	_
61-47	11261-11264	the	_
61-48	11265-11273	included	_
61-49	11274-11284	behavioral	_
61-50	11285-11290	tests	_
61-51	11291-11293	as	_
61-52	11294-11298	well	_
61-53	11299-11301	as	_
61-54	11302-11305	ROI	_
61-55	11306-11310	FCDs	_
61-56	11311-11312	.	_

Text=The number of components selected from ROI FCDs was limited to 1 for each behavioral category.
62-1	11313-11316	The	_
62-2	11317-11323	number	_
62-3	11324-11326	of	_
62-4	11327-11337	components	_
62-5	11338-11346	selected	_
62-6	11347-11351	from	_
62-7	11352-11355	ROI	_
62-8	11356-11360	FCDs	_
62-9	11361-11364	was	_
62-10	11365-11372	limited	_
62-11	11373-11375	to	_
62-12	11376-11377	1	_
62-13	11378-11381	for	_
62-14	11382-11386	each	_
62-15	11387-11397	behavioral	_
62-16	11398-11406	category	_
62-17	11407-11408	.	_

Text=For significance testing of the contribution of each ROI FCD to component scores, a permutation approach was used (N = 100000) to extract the null distribution of component loadings.
63-1	11409-11412	For	_
63-2	11413-11425	significance	_
63-3	11426-11433	testing	_
63-4	11434-11436	of	_
63-5	11437-11440	the	_
63-6	11441-11453	contribution	_
63-7	11454-11456	of	_
63-8	11457-11461	each	_
63-9	11462-11465	ROI	_
63-10	11466-11469	FCD	_
63-11	11470-11472	to	_
63-12	11473-11482	component	_
63-13	11483-11489	scores	_
63-14	11490-11491	,	_
63-15	11492-11493	a	_
63-16	11494-11505	permutation	_
63-17	11506-11514	approach	_
63-18	11515-11518	was	_
63-19	11519-11523	used	_
63-20	11524-11525	(	_
63-21	11526-11527	N	_
63-22	11528-11529	=	_
63-23	11530-11536	100000	_
63-24	11537-11538	)	_
63-25	11539-11541	to	_
63-26	11542-11549	extract	_
63-27	11550-11553	the	_
63-28	11554-11558	null	_
63-29	11559-11571	distribution	_
63-30	11572-11574	of	_
63-31	11575-11584	component	_
63-32	11585-11593	loadings	_
63-33	11594-11595	.	_

Text=All the p-values for PLS regression analysis are reported for a two-tailed test (i.e., considering positive and negative loadings).
64-1	11596-11599	All	_
64-2	11600-11603	the	_
64-3	11604-11612	p-values	_
64-4	11613-11616	for	_
64-5	11617-11620	PLS	_
64-6	11621-11631	regression	_
64-7	11632-11640	analysis	_
64-8	11641-11644	are	_
64-9	11645-11653	reported	_
64-10	11654-11657	for	_
64-11	11658-11659	a	_
64-12	11660-11670	two-tailed	_
64-13	11671-11675	test	_
64-14	11676-11677	(	_
64-15	11678-11682	i.e.	_
64-16	11683-11684	,	_
64-17	11685-11696	considering	_
64-18	11697-11705	positive	_
64-19	11706-11709	and	_
64-20	11710-11718	negative	_
64-21	11719-11727	loadings	_
64-22	11728-11729	)	_
64-23	11730-11731	.	_

